Skip to main content


08-10-2021 | Artificial pancreas systems | News

Fully closed-loop insulin delivery not yet a match for precise carb counting

A dual-hormone fully closed-loop system did not demonstrate non-inferiority to a hybrid system in a randomized trial, despite producing a high time in range, report the researchers.

05-10-2021 | EASD 2021 | Conference coverage | News

Omnipod DASH benefits confirmed in real-world study

Children and adults with type 1 diabetes achieve significant reductions in glycated hemoglobin and hypoglycemic events during their first 90 days of using the Omnipod DASH insulin pump system, show real-world data.

04-10-2021 | EASD 2021 | Conference coverage | News

Real-world data show comparable benefits for second-generation insulins in type 2 diabetes

Insulin-naïve people with type 2 diabetes initiating the second-generation basal insulins glargine 300 or degludec 100 experience similar improvements in glycated hemoglobin levels, show data from the real-world RESTORE-2 study.

04-10-2021 | EASD 2021 | Conference coverage | News

SoliMix trial supports iGlarLixi for type 2 diabetes

Findings from the SoliMix trial indicate that iGlarLixi may improve glycemic control with weight benefit compared with BIAsp 30 among people with suboptimally controlled type 2 diabetes on basal insulin.

29-09-2021 | EASD 2021 | Conference coverage | News

No difference in hypoglycemia duration with insulin icodec vs insulin glargine in type 2 diabetes

People with type 2 diabetes receiving the once-weekly basal insulin analog insulin icodec have similar hypoglycemic episode durations to those given insulin glargine, regardless of titration algorithm, initial loading dose, or prior insulin use, study findings indicate.

22-09-2021 | Faster-acting insulin aspart | News

Real-world backing for glycemic benefits of faster aspart

Switching to fast-acting insulin aspart is associated with an increased time in range and reduced glycemic variability, show data from a real-world observational study.

15-09-2021 | Retinopathy | News

Risk factors for early retinopathy in type 2 diabetes revealed

Factors including insulin use and ethnicity can help predict who will develop proliferative diabetic retinopathy within 5 years after type 2 diabetes diagnosis, say researchers.

14-09-2021 | Empagliflozin | News

Empagliflozin may reduce insulin requirements in type 2 diabetes

Use of the SGLT2 inhibitor empagliflozin in people with type 2 diabetes and cardiovascular disease may reduce rates of insulin initiation or intensification, suggests a post-hoc analysis of the EMPA-REG OUTCOME trial.

Image Credits